NCT02281058

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are performing a pilot study for the treatment of new onset or actively progressing vitiligo with abatacept to determine if weekly self-injections of medication lead to clinical improvement in vitiligo lesions.

Detailed description

Abatacept has been shown to decrease T cell activity and reduce symptoms associated with rheumatoid arthritis. Similar pathways have been shown to be involved in vitiligo. Therefore, we are recruiting 10 adult patients with active vitiligo who meet specific inclusion and exclusion criteria to receive self-administered injections of abatacept weekly starting at week 0 and continuing until week 24. A 32 week follow-up visit will be performed to evaluate secondary endpoints as well. We will be monitoring patients to see if skin lesions of vitiligo stop spreading and start to repigment with continued treatment.

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	Abatacept	self-injected subcutaneous biologic medication

Timeline

• Start date: 2015-01-01
• Primary completion: 2017-11-01
• Completion: 2018-05-01
• First posted: 2014-11-03
• Last updated: 2017-08-09

Locations

1 site across 1 country: United States